Abstract
It has been clearly demonstrated that left ventricular (LV) hypertrophy is a strong blood pressure independent risk factor for cardiovascular morbidity and mortality in the general population, in primary and secondary hypertension and in cardiac patients. LV hypertrophy in arterial hypertension develops in response to an increased afterload, but underlying pathophysiological mechanisms include a variety of non-haemodynamic factors. Due to the prognostic importance of LV hypertrophy, normalisation of LV mass emerged as a desirable goal of antihypertensive treatment. Indeed, several prospective studies now indicate that regression of LV hypertrophy reduced cardiovascular complications. As a consequence, the question was raised whether certain antihypertensive drugs differ in their ability to reduce LV mass. Several comparative studies and meta-analyses have been carried out to resolve this issue. The available data seem to indicate that angiotensin-converting enzyme (ACE)-inhibitors and calcium channel blockers were more potent than β-blockers in their ability to reduce LV hypertrophy, with diuretics in the intermediate range. The role of new antihypertensive agents such as angiotensin II AT1-receptor blockers appears similar to the one of ACE-inhibitors, since in some studies angiotensin II AT1-receptor blockers were superior to β-blockers and diuretics. Various aspects of LV hypertrophy including its prevalence, determinants, prognosis and regression are discussed in this article.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmieder, R., Messerli, F. Hypertension and the heart. J Hum Hypertens 14, 597–604 (2000). https://doi.org/10.1038/sj.jhh.1001044
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001044
Keywords
This article is cited by
-
Welche kardiale Diagnostik braucht Ihr Hypertoniker?
MMW - Fortschritte der Medizin (2014)
-
Effect of hypertension on echocardiographic parameters in rheumatoid arthritis
Zeitschrift für Rheumatologie (2014)
-
Relationships between metabolic syndrome and left ventricular mass in hypertensive patients: does sex matter?
Journal of Human Hypertension (2008)
-
Effect of Yiqi Huoxue Recipe (益气活血方) on cardiac function and ultrastructure in regression of pressure overload-induced myocardial hypertrophy in rats
Chinese Journal of Integrative Medicine (2007)
-
Hypertension, Na+/Ca2+ exchanger, and Na+, K+-ATPase
Kidney International (2006)